Kodiak Sciences Inc
K27
Company Profile
Business description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Contact
1200 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
121
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
Guidance reaffirmed and UK implementation on track.
stocks
The sectors set to soar on government spending
Governments worldwide love to spend more money, and there are no signs that it will change any time soon.
stocks
Chart of the Week: How private companies are reshaping public markets
Our latest take from the US Manager Research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,098.60 | 9.70 | -0.11% |
| CAC 40 | 8,032.11 | 42.12 | -0.52% |
| DAX 40 | 24,031.80 | 17.94 | -0.07% |
| Dow JONES (US) | 47,311.00 | 225.76 | 0.48% |
| FTSE 100 | 9,751.01 | 26.07 | -0.27% |
| HKSE | 26,485.90 | 550.49 | 2.12% |
| NASDAQ | 23,499.80 | 151.16 | 0.65% |
| Nikkei 225 | 50,883.68 | 671.41 | 1.34% |
| NZX 50 Index | 13,576.81 | 44.17 | -0.32% |
| S&P 500 | 6,796.29 | 24.74 | 0.37% |
| S&P/ASX 200 | 8,828.30 | 8.50 | -0.10% |
| SSE Composite Index | 4,007.76 | 38.51 | 0.97% |